<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00478</drugbank-id>
  <drugbank-id>APRD01219</drugbank-id>
  <name>Rimantadine</name>
  <description>An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.</description>
  <cas-number>13392-28-4</cas-number>
  <unii>0T2EF4JQTU</unii>
  <average-mass>179.3018</average-mass>
  <monoisotopic-mass>179.167399677</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults.</indication>
  <pharmacodynamics>Rimantadine, a cyclic amine, is a synthetic antiviral drug and a derivate of adamantane, like a similar drug amantadine. Rimantadine is inhibitory to the in vitro replication of influenza A virus isolates from each of the three antigenic subtypes (H1N1, H2H2 and H3N2) that have been isolated from man. Rimantadine has little or no activity against influenza B virus. Rimantadine does not appear to interfere with the immunogenicity of inactivated influenza A vaccine.</pharmacodynamics>
  <mechanism-of-action>The mechanism of action of rimantadine is not fully understood. Rimantadine appears to exert its inhibitory effect early in the viral replicative cycle, possibly inhibiting the uncoating of the virus. The protein coded by the M2 gene of influenza A may play an important role in rimantadine susceptibility.</mechanism-of-action>
  <toxicity>Oral LD&lt;sub&gt;50&lt;/sub&gt; in rats is 640 mg/kg. Overdoses of a related rug, amantadine, have been reported with adverse reactions consisting of agitation, hallucinations, cardiac arrhythmia and death.</toxicity>
  <metabolism>Following oral administration, rimantadine is extensively metabolized in the liver with less than 25% of the dose excreted in the urine as unchanged drug. Glucuronidation and hydroxylation are the major metabolic pathways.</metabolism>
  <absorption>Well absorbed, with the tablet and syrup formulations being equally absorbed after oral administration.</absorption>
  <half-life>25 to 30 hours in young adults (22 to 44 years old). Approximately 32 hours in elderly (71 to 79 years old) and in patients with chronic liver disease. Approximately 13 to 38 hours in children (4 to 8 years old).</half-life>
  <protein-binding>Approximately 40% over typical plasma concentrations.</protein-binding>
  <route-of-elimination>Following oral administration, rimantadine is extensively metabolized in the liver with less than 25% of the dose excreted in the urine as unchanged drug.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as monoalkylamines. These are organic compounds containing an primary aliphatic amine group.</description>
    <direct-parent>Monoalkylamines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic nitrogen compounds</superclass>
    <class>Organonitrogen compounds</class>
    <subclass>Amines</subclass>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aliphatic homopolycyclic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary aliphatic amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000833</drugbank-id>
      <name>Rimantadine hydrochloride</name>
      <unii>JEI07OOS8Y</unii>
      <cas-number>1501-84-4</cas-number>
      <inchikey>OZBDFBJXRJWNAV-UHFFFAOYSA-N</inchikey>
      <average-mass>215.763</average-mass>
      <monoisotopic-mass>215.144077416</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">alpha-Methyl-1-adamantanemethylamine</synonym>
    <synonym language="english" coder="">alpha-Methyladamantanemethylamine</synonym>
    <synonym language="spanish" coder="inn">Rimantadina</synonym>
    <synonym language="english" coder="inn">Rimantadine</synonym>
    <synonym language="latin" coder="inn">Rimantadinum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Flumadine</name>
      <labeller>FOREST PHARMACEUTICALS, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0456-0521</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flumadine</name>
      <labeller>FOREST PHARMACEUTICALS, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0456-0527</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Syrup</dosage-form>
      <strength>50 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flumadine</name>
      <labeller>Caraco Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49708-521</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA019649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flumadine</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3441</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-22</started-marketing-on>
      <ended-marketing-on>2010-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA019649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rimantadine Hydrochloride</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rimantadine Hydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-5029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-11-02</started-marketing-on>
      <ended-marketing-on>2012-03-31</ended-marketing-on>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075916</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rimantadine Hydrochloride</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rimantadine Hydrochloride</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-2103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rimantadine Hydrochloride</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1775</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rimantadine Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1911</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rimantadine Hydrochloride</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3552</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076132</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Rimantalist</name>
      <labeller>Physician Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code>68405-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Flumadine</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Flumadine</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Flumadine</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Rimantalist</name>
      <ingredients>Arginine + Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Rimantadine Hydrochloride</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Rimantadine Hydrochloride</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Rimantadine Hydrochloride</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Rimantadine Hydrochloride</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Flumadine</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Rimantadine Hydrochloride</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Rimantadine Hydrochloride</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
    <mixture>
      <name>Rimantadine Hydrochloride</name>
      <ingredients>Rimantadine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Caraco Pharmaceutical Labs</name>
      <url>http://www.caraco.com</url>
    </packager>
    <packager>
      <name>Corepharma LLC</name>
      <url>http://www.corepharma.com</url>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>Forest Pharmaceuticals</name>
      <url>http://www.forestpharm.com</url>
    </packager>
    <packager>
      <name>Global Pharmaceuticals</name>
      <url>http://www.globalphar.com</url>
    </packager>
    <packager>
      <name>H.J. Harkins Co. Inc.</name>
      <url>http://hjharkinscompanyinc.com</url>
    </packager>
    <packager>
      <name>Impax Laboratories Inc.</name>
      <url>http://www.impaxlabs.com</url>
    </packager>
    <packager>
      <name>Inwood Labs</name>
      <url>http://www.inwoodlabs.com</url>
    </packager>
    <packager>
      <name>McNeil Laboratories</name>
      <url/>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Ortho-McNeil-Janssen Pharmaceuticals Inc.</name>
      <url>http://www.ortho-mcneil.com</url>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Prescript Pharmaceuticals</name>
      <url>http://www.prescript.net</url>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>Vistakon Pharmaceuticals LLC</name>
      <url>http://vistakonpharmaceutical.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Forest laboratories inc</manufacturer>
    <manufacturer generic="false" url="">Caraco pharmaceutical laboratories ltd</manufacturer>
    <manufacturer generic="true" url="">Actavis totowa llc</manufacturer>
    <manufacturer generic="true" url="">Corepharma llc</manufacturer>
    <manufacturer generic="true" url="">Impax laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Levaquin i.v. 25 mg/ml vial</description>
      <cost currency="USD">1.94</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Flumadine 100 mg tablet</description>
      <cost currency="USD">2.4</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Rimantadine hcl 100 mg tablet</description>
      <cost currency="USD">2.44</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Quixin 0.5% eye drops</description>
      <cost currency="USD">12.21</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Levaquin 250 mg tablet</description>
      <cost currency="USD">14.09</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Levaquin 500 mg tablet</description>
      <cost currency="USD">14.69</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Iquix 1.5% eye drops</description>
      <cost currency="USD">15.71</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Levaquin 750 mg leva-pak tablet</description>
      <cost currency="USD">27.51</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Levaquin 750 mg tablet</description>
      <cost currency="USD">27.51</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Levofloxacin hemihydr 100% powder</description>
      <cost currency="USD">42.69</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Levaquin 500 mg/100 ml d5w</description>
      <cost currency="USD">0.44</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adamantanes</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Cyclic Amines</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cycloparaffins</category>
      <mesh-id>D003516</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Influenza A M2 Protein Inhibitor</category>
      <mesh-id/>
    </category>
    <category>
      <category>M2 Protein Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nucleic Acid Synthesis Inhibitors</category>
      <mesh-id>D019384</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Human Influenza A Virus</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Syrup</form>
      <route>Oral</route>
      <strength>50 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J05AC02">
      <level code="J05AC">Cyclic amines</level>
      <level code="J05A">DIRECT ACTING ANTIVIRALS</level>
      <level code="J05">ANTIVIRALS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00478.pdf?1265922807</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00478.pdf?1265922745</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Rimantadine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.28</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>9.15e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1-(adamantan-1-yl)ethan-1-amine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>rimantadine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>179.3018</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>179.167399677</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(N)C12CC3CC(CC(C3)C1)C2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H21N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>UBCHPRBFMUDMNC-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>26.02</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>54.52</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>21.79</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>10.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Hydrochloride salt freely soluble (50 mg/ml at 20 °C)</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>&gt;300 °C</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>94440</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5071</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505973</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07236</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D08483</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4893</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50216627</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164748038</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001087</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Rimantadine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL959</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/rimantadine.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/rimantadine.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000630</id>
      <name>Matrix protein 2</name>
      <organism>Influenza A virus (strain A/Ann Arbor/6/1960 H2N2)</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A4968</ref-id>
            <pubmed-id>18669647</pubmed-id>
            <citation>Jing X, Ma C, Ohigashi Y, Oliveira FA, Jardetzky TS, Pinto LH, Lamb RA: Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10967-72. doi: 10.1073/pnas.0804958105. Epub 2008 Jul 31.</citation>
          </article>
          <article>
            <ref-id>A4969</ref-id>
            <pubmed-id>19215710</pubmed-id>
            <citation>Melidou A, Kyriazopoulou V, Diza E, Alexiou S, Pierroutsakos Y: Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104.</citation>
          </article>
          <article>
            <ref-id>A4970</ref-id>
            <pubmed-id>19917240</pubmed-id>
            <citation>Chuang GY, Kozakov D, Brenke R, Beglov D, Guarnieri F, Vajda S: Binding hot spots and amantadine orientation in the influenza a virus M2 proton channel. Biophys J. 2009 Nov 18;97(10):2846-53. doi: 10.1016/j.bpj.2009.09.004.</citation>
          </article>
          <article>
            <ref-id>A4971</ref-id>
            <pubmed-id>18620883</pubmed-id>
            <citation>Intharathep P, Laohpongspaisan C, Rungrotmongkol T, Loisruangsin A, Malaisree M, Decha P, Aruksakunwong O, Chuenpennit K, Kaiyawet N, Sompornpisut P, Pianwanit S, Hannongbua S: How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J Mol Graph Model. 2008 Oct;27(3):342-8. doi: 10.1016/j.jmgm.2008.06.002. Epub 2008 Jun 8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P21430" source="Swiss-Prot">
        <name>Matrix protein 2</name>
        <general-function>Ion channel activity</general-function>
        <specific-function>Forms a proton-selective ion channel that is necessary for the efficient release of the viral genome during virus entry. After attaching to the cell surface, the virion enters the cell by endocytosis. Acidification of the endosome triggers M2 ion channel activity. The influx of protons into virion interior is believed to disrupt interactions between the viral ribonucleoprotein (RNP), matrix protein 1 (M1), and lipid bilayers, thereby freeing the viral genome from interaction with viral proteins and enabling RNA segments to migrate to the host cell nucleus, where influenza virus RNA transcription and replication occur. Also plays a role in viral proteins secretory pathway. Elevates the intravesicular pH of normally acidic compartments, such as trans-Golgi network, preventing newly formed hemagglutinin from premature switching to the fusion-active conformation (By similarity).</specific-function>
        <gene-name>M</gene-name>
        <locus/>
        <cellular-location>Virion membrane</cellular-location>
        <transmembrane-regions>23-43</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>4.87</theoretical-pi>
        <molecular-weight>11165.62</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="384498">Influenza A virus (strain A/Ann Arbor/6/1960 H2N2)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M23978</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>324265</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21430</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>M2_I60A0</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Proton channel protein M2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001256|Matrix protein 2
MSLLTEVETPIRNEWGCRCNDSSDPLVVAASIIGILHLILWILDHLFFKCIYRFFKHGLK
RGPSTEGVPESMREEYRKEQQSAVDADDSHFVSIELE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0001255|294 bp
ATGAGTCTTCTAACCGAGGTCGAAACGCCTATCAGAAACGAATGGGGGTGCAGATGCAAC
GATTCAAGTGACCCTCTTGTTGTTGCCGCGAGTATCATTGGGATCTTGCACTTGATATTG
TGGATTCTTGATCATCTTTTTTTCAAATGCATTTATCGCTTCTTTAAACACGGTCTGAAA
AGAGGGCCTTCTACGGAAGGAGTACCAGAGTCTATGAGGGAAGAATATCGAAAGGAACAG
CAGAGTGCTGTGGATGCTGACGATAGTCATTTTGTCAGCATAGAGCTGGAGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00599</identifier>
            <name>Flu_M2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>host cell plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral to membrane of host cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>virion membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hydrogen ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pore formation by virus in membrane of host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host autophagy</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>